Aleix Prat Selected Research

Proteins (Proteins, Gene)

4/2024	Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial.
1/2022	High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer.
1/2021	RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.
1/2020	What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer?
8/2014	Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer.
1/2013	Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Aleix Prat Research Topics

Disease

151	Breast Neoplasms (Breast Cancer) 04/2024 - 06/2007
136	Neoplasms (Cancer) 05/2024 - 06/2007
19	Neoplasm Metastasis (Metastasis) 03/2024 - 11/2007
18	Triple Negative Breast Neoplasms 11/2022 - 04/2012
14	COVID-19 01/2024 - 07/2020
12	Pathologic Complete Response 04/2024 - 09/2013
9	Prostatic Neoplasms (Prostate Cancer) 03/2024 - 04/2014
8	Disease Progression 12/2023 - 05/2008
5	Melanoma (Melanoma, Malignant) 08/2020 - 01/2016
4	Carcinoma (Carcinomatosis) 01/2022 - 12/2013
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 11/2009
3	Neutropenia 11/2023 - 01/2020
3	Brain Neoplasms (Brain Tumor) 09/2023 - 01/2011
3	Hypoxia (Hypoxemia) 06/2021 - 04/2012
3	Residual Neoplasm 08/2020 - 01/2019
2	Sarcoma (Soft Tissue Sarcoma) 01/2024 - 01/2023
2	Infections 11/2022 - 01/2022
2	Fatigue 10/2022 - 01/2021
2	Death (Near-Death Experience) 01/2021 - 01/2018
2	Lung Neoplasms (Lung Cancer) 04/2020 - 01/2018
2	Circulating Neoplastic Cells 01/2020 - 01/2020
2	Exanthema (Rash) 01/2019 - 11/2009
2	Colorectal Neoplasms (Colorectal Cancer) 12/2017 - 02/2016
2	Glioblastoma (Glioblastoma Multiforme) 11/2017 - 02/2012

Drug/Important Bio-Agent (IBA)

55	Hormones (Hormone)IBA 05/2024 - 09/2008
49	Phenobarbital (Luminal)FDA Link 05/2024 - 01/2010
40	Biomarkers (Surrogate Marker)IBA 03/2024 - 11/2009
33	Trastuzumab (Herceptin)FDA Link 04/2024 - 05/2008
18	Estrogen ReceptorsIBA 10/2023 - 01/2010
15	human ERBB2 proteinIBA 04/2024 - 09/2008
14	RNA (Ribonucleic Acid)IBA 03/2024 - 09/2013
14	ClaudinsIBA 12/2015 - 01/2010
12	Docetaxel (Taxotere)FDA Link 04/2024 - 11/2016
12	ErbB Receptors (EGF Receptor)IBA 12/2023 - 09/2008
12	Messenger RNA (mRNA)IBA 06/2023 - 09/2015
11	pertuzumabIBA 04/2024 - 01/2019
11	Immune Checkpoint InhibitorsIBA 11/2023 - 01/2016
11	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 04/2012
9	Lapatinib (GW572016)FDA Link 01/2023 - 02/2014
8	Letrozole (Femara)FDA LinkGeneric 03/2024 - 06/2011
8	AnthracyclinesIBA 01/2023 - 04/2013
8	Taxoids (Taxanes)IBA 10/2022 - 11/2016
7	Carboplatin (JM8)FDA LinkGeneric 04/2024 - 02/2017
7	ribociclibIBA 03/2024 - 01/2020
7	taxaneIBA 11/2020 - 09/2013
6	Proteins (Proteins, Gene)FDA Link 04/2024 - 01/2013
6	Immunoconjugates (Immunoconjugate)IBA 10/2023 - 01/2021
6	ParaffinIBA 01/2023 - 01/2014
6	Paclitaxel (Taxol)FDA LinkGeneric 01/2023 - 04/2013
6	Formaldehyde (Formol)FDA Link 01/2023 - 01/2014
6	Fulvestrant (Faslodex)FDA Link 01/2022 - 10/2013
5	Oxygen (Dioxygen)IBA 01/2024 - 01/2022
5	palbociclibIBA 12/2023 - 11/2020
5	trastuzumab deruxtecanIBA 10/2023 - 10/2021
5	AlpelisibIBA 01/2022 - 04/2015
5	Progesterone Receptors (Progesterone Receptor)IBA 01/2019 - 01/2010
4	Aromatase InhibitorsIBA 10/2023 - 06/2011
4	Ado-Trastuzumab EmtansineIBA 01/2023 - 07/2020
4	Estrogens (Estrogen)FDA Link 01/2023 - 09/2008
4	Poly(ADP-ribose) Polymerase InhibitorsIBA 12/2022 - 11/2012
4	Androgen Receptors (Androgen Receptor)IBA 10/2021 - 04/2014
4	exemestane (Aromasin)FDA Link 01/2021 - 06/2011
4	Phosphotransferases (Kinase)IBA 01/2018 - 10/2013
3	AndrogensIBA 03/2024 - 04/2014
3	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2024 - 01/2020
3	Anastrozole (Arimidex)FDA LinkGeneric 12/2023 - 06/2011
3	atezolizumabIBA 10/2022 - 08/2020
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 09/2022 - 01/2017
3	eribulin FDA Link 11/2021 - 01/2021
3	Everolimus FDA Link 01/2021 - 01/2019
3	pembrolizumabIBA 01/2021 - 01/2016
3	Interleukin-11 (Interleukin 11)IBA 02/2017 - 01/2013
3	IpilimumabIBA 12/2016 - 01/2016
2	Immunoglobulin G (IgG)IBA 03/2024 - 01/2023
2	COVID-19 VaccinesIBA 01/2024 - 01/2022
2	NivolumabIBA 12/2023 - 01/2017
2	Cyclin-Dependent Kinase 4IBA 12/2023 - 01/2021
2	Epidermal Growth Factor (EGF)IBA 12/2023 - 10/2019
2	Tumor Biomarkers (Tumor Markers)IBA 11/2023 - 01/2023
2	Circulating Tumor DNAIBA 01/2023 - 02/2021
2	Monoclonal AntibodiesIBA 11/2022 - 09/2008
2	AntibodiesIBA 10/2022 - 01/2017
2	Tyrosine Kinase InhibitorsIBA 01/2022 - 10/2016
2	Tamoxifen FDA LinkGeneric 02/2021 - 01/2013
2	CytokinesIBA 01/2021 - 10/2016
2	Interleukin-6 (Interleukin 6)IBA 01/2021 - 10/2016
2	Antiviral Agents (Antivirals)IBA 01/2021 - 01/2021
2	NVP-BKM120IBA 11/2020 - 11/2012
2	LigandsIBA 01/2020 - 10/2013
2	olaparibIBA 12/2019 - 11/2012
2	MicroRNAs (MicroRNA)IBA 02/2017 - 01/2013
2	Programmed Cell Death 1 ReceptorIBA 01/2017 - 01/2016

Therapy/Procedure

109	Therapeutics 04/2024 - 06/2007
48	Drug Therapy (Chemotherapy) 04/2024 - 06/2007
20	Neoadjuvant Therapy 04/2024 - 12/2015
8	Castration 03/2024 - 11/2016
7	Immunotherapy 06/2023 - 01/2020
4	Radiotherapy 11/2023 - 06/2007
3	Adjuvant Chemotherapy 02/2023 - 01/2016
2	Palliative Care (Palliative Therapy) 01/2021 - 01/2018